- Data shows diagnostic test capable of detecting primary source of cancers with high level of accuracy and specificity across 15 different tumour types.
- Commercial launch expected March/April 2012.
Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that Dr Keith Byron, Scientific Director of Healthscope Advanced Pathology, publically presented data for the first time in respect of Circadian’s novel diagnostic technology for “Cancers of Unknown Primary” (CUP), at the “Science and the City” meeting of the Royal College of Pathologists of Australia currently being held in Sydney.
The poster presentation entitled “Development of a Gene Expression Based Assay to Determine the Origin of Metastatic Carcinomas of Unknown Primary” (copy attached) showed that the CUP test was able to detect actual primary source of tumour type with 93% accuracy within the first three predictions and had 98.5% specificity across 15 different tumour types.
The diagnostic test method has been developed in collaboration between Circadian, Healthscope, the Peter MacCallum Cancer Centre, a leading specialty cancer centre, and scientists at NICTA, Australia’s Information and Communications Technology (ICT) Research Centre of Excellence.
For further information please download PDF below: